# **Colts**

A research initiative by Canaccord Genuity


# AVA Risk Group (ASX.AVA)

Strong 4Q20 bodes well for FY21

Key Facts	
Company Code	AVA
Closing Price (30/07/20)	\$0.26
Date of Report	31/07/20
Company Website	www.theavagroup.com
Analyst	Aaron Muller

Company Statistics	
12-Month Range (A\$)	\$0.26-\$0.08
Market Cap (A\$Mil)	\$61m
Issued Shares (Mil)	234.1m
Issued Options (Mil)	\$9.95m
Cash (A\$Mil)	\$7.9m





Canaccord Colts provide research coverage on a select group of early-stage ASX-listed microcap companies that our institutional research team believes have strong development trajectories.



If you have received this indirectly, please click <u>here</u> to receive future research on AVA and other Colt companies.



### Cash continues to roll in

AVA reported a strong 4Q20 posting a record quarterly operating cash flow of \$4.0m and ended the year with net cash of \$7.9m. The result was underpinned by an improved performance from the Services division, the continued delivery of the Indian Ministry of Defence (IMOD) contract, and cost reductions across the business, which has helped lift margins. This helped to offset the impact of Covid-19 on the Technology division, which saw order delays of ~\$2.5m during the quarter.

As a result of the strong quarter, AVA has guided to FY20 revenue of ~\$45m and EBITDA of \$6.8m. This compares to our estimates of \$43.6m and \$5.7m – a 19% beat at the EBITDA line. With the Services division seeing an acceleration of revenue growth and gross margins, we have revised our FY21 EBITDA estimate by 18% to \$9.8m. We have also increased our Target Price to \$0.38 per share. We retain our BUY rating.

## **Key points**

Logistics underpinned strong 4Q20 result – Group revenue for 4Q20 of \$12.3m takes 2H20 revenue to \$24.6m (+50% on pcp). FY20 EBITDA guidance of ~\$6.8m implies 4Q20 EBITDA of \$2.6m and 2H20 EBITDA of \$4.6m (1H20: \$2.2m). The Services division outperformed expectations despite the impact of Covid-19 on airfreight capacity. 4Q20 revenue of \$9.7m was +59% on 3Q20. Management was able to respond quickly to the changes given its capital light model, which resulted in an acceleration and conversion of new customers. This bodes well for growth in FY21. In addition, Services division gross margins improved in line with higher freight costs - gross margins were 25% in FY20 vs 21% in FY19. This strong performance offset order delays in the Technology division due to Covid-19, which management called out as being \$2.5m. Revenue for 4Q20 of \$2.5m was down on the \$6.1m in 3Q20. The order backlog remains at ~\$16m, which we expect to be delivered in FY21.

IMOD continues to bring in the cash – AVA continued to deliver on its data network security contract with the Indian Ministry of Defence (IMOD). During the quarter, \$1.3m of revenue was recognised taking total revenue from the contract in FY20 to \$5.0m. During 4Q20, \$1.5m in cash was received. This, together with improved an improvement in working capital saw net cash increase to \$7.9m. With additional IMOD payments to be received in 1H21 of \$3.9m, we expect cash reserves could grow to ~\$12-14m by 31 December 2020.

**Strong growth outlook remains** – With strong momentum in Services, a technology order backlog of ~\$16m and the IMOD project being delivered on, FY21 is expected to deliver strong growth. A recent contract win by AVA's technology division with the Australian Department of Defence and the commercialisation of AVA's conveyor health monitoring solution, the Aura IQ, are also likely to contribute. There is some risk that Covid-19 related delays continue to impact the Technology division, however, as we saw with 4Q20, this would likely benefit AVA's Services division.

**Valuation and recommendation** – We have made some adjustments to our forecasts to reflect the result – FY20 EPS +14% to 1.9c and FY21 EPS +15% to 3.2c Consequently, we have increased our valuation and Target Price to \$0.38 per share. At current levels AVA is trading on a FY21 PER of 8.2x and an EV/EBITDA multiple of 4.6x, which isn't that demanding considering the growth profile and cashed up balance sheet. We retain our BUY rating.

# AVA Financial Summary

Profit & Loss (\$m)	2018A	2019A	2020F	2021F
Sales Revenue	19.8	33.1	45.0	53.1
EBITDA	-3.1	-2.8	6.8	9.8
Depreciation	-0.4	-0.7	-1.2	-1.2
EBITA	-3.5	-3.5	5.6	8.6
Amortisation	-1.1	-1.2	-1.2	-1.2
EBIT	-4.6	-4.7	4.4	7.4
Net Interest Expense	0.1	0.0	0.0	0.0
NPBT	-4.5	-4.7	4.4	7.4
Tax expense	1.1	0.0	0.0	0.0
NPAT (Normalised)	-3.5	-4.7	4.4	7.4
Significant items	0.0	0.0	0.0	0.0
NPAT (Reported)	-3.5	-4.7	4.4	7.4
Cash Flow (\$m)	2018A	2019A	2020F	2021F
Operating EBITDA	-3.1	-2.8	6.8	9.8
- Interest & Tax Paid	0.1	1.0	0.0	0.0
+/- change in Work. Cap.	2.1	-0.6	-0.9	-1.2
- other	1.3	-0.9	0.0	0.0
Operating Cashflow	0.4	-3.3	5.9	8.6
- Capex	0.0	-0.2	-1.0	-1.0
- Aquisitions/divestments	-1.3	-1.1	0.0	0.0
- other	0.0	-1.2	0.0	0.0
Free Cashflow	-1.0	-5.8	4.9	7.6
- Ord Dividends	0.0	0.0	0.0	0.0
- Equity /other	0.0	3.0	0.0	0.0
Net Cashflow	-1.0	-2.8	4.9	7.6
Cash at beginning of period	6.9	5.9	3.0	7.9
+/- borrowings / other	0.0	0.0	0.0	0.0
Cash at end of period	5.9	3.0	7.9	15.5
Balance Sheet	2018A	2019A	2020F	2021F
Cash	5.9	3.1	7.9	15.5
Inventories	4.3	4.5	4.6	5.4
Debtors	5.3	5.0	7.3	8.7
PPE	0.9	0.8	2.2	3.2
Intangibles	12.7	12.7	12.7	12.7
Other assets	0.5	0.4	0.4	0.4
Total Assets	29.7	26.5	35.0	45.8
Borrowings	0.0	0.7	0.0	0.0
Trade Creditors	4.8	4.0	5.5	6.5
Other Liabilities	1.6	1.5	1.5	1.5
Total Liabilities	6.4	6.3	7.0	8.0
NET ASSETS	23.3	20.2	28.0	37.8
Board and Management				
	Shares	%	Options	%
David Cronin - Chairman	33.9	14.5%	0.0	0.0%
Robert Broomfield - CEO	3.0	1.3%	1.8	17.6%
Mark Stevens - Non Exec-Director	0.5	0.0%	0.0	0.0%
Mike McGeever - Non Exec-Director	4.1	0.0%	0.0	0.0%

#### Description

AVA is a leader in fibre optic intrusion detection systems which detect and locate perimeter intrusions, oil and gas pipeline interference and data network tapping. FFT has more than 1500 systems deployed in over 60 countries. AVA also offers access security products and secure logistics.

Valuation ratios	2018A	2019A	2020F	2021F
EPS (cps)	-2.1	-2.0	1.9	3.2
P/E (x)	-12.6	-12.9	13.8	8.2
PER Rel - All Ind.	-162%	-169%	-20%	-49%
PER Rel - Small Ind.	-165%	-171%	-17%	-46%
Enterprise Value (\$m)	55.0	58.5	52.9	45.4
EV / EBITDA (x)	-17.6	-20.5	7.8	4.6
EV / EBIT (x)	-11.9	-12.4	12.0	6.1
DPS (cps)	0.0	0.0	0.0	1.1
Dividend Yield (%)	0.0%	0.0%	0.0%	4.4%
Franking (%)	100%	100%	100%	100%
CFPS (cps)	0.2	-1.4	2.5	3.7
P / CFPS (x)	120.7	-18.4	10.3	7.1
Profitability ratios	2018A	2019A	2020F	2021F
EBITDA Margin (%)	-15.7	-8.6	15.1	18.5
EBIT Margin (%)	-23.2	-14.3	9.8	13.9
ROE (%)	-15.1	-23.4	29.4	37.1
ROA (%)	-19.4	-20.1	16.2	24.4
ROIC (%)	-20.4	-19.7	nm	nm
Balance Sheet ratios	2018A	2019A	2020F	2021F
Net Debt (cash)	-5.9	-2.4	-8.0	-15.5
Net Gearing (%)	cash	cash	cash	cash
Interest Cover (x)	nm	nm	nm	nm
NTA per share (\$)	0.15	0.07	0.04	0.06
Price / NTA (x)	1.8	4.0	6.1	4.1
EFPOWA (m)	166.7	234.1	234.1	234.1
Growth ratios	2018A	2019A	2020F	2021F
Sales revenue (\$m)	53.7%	66.9%	36.0%	18.0%
EBITDA (\$m)	nm	nm	nm	44.0%
EBIT (\$m)	nm	nm	nm	68.0%
NPAT (\$m)	nm	nm	nm	68.0%
EPS (cps)	nm	nm	nm	68.0%
DPS (cps)	na	na	na	na
Interim Analysis	1H18A	2H18A	1H19A	2H19A
Revenue	8.2	11.6	16.7	16.9
EBITDA	0.6	-3.7	-1.6	-1.2
EBITDA margin	nm	-31.6%	-9.6%	-7.4%
Valuation				2020F
Normalised EBITDA multiple (x)				
EBITDA (\$m)				9.8
Target EBITDA multiple (x)				7.5
Net Debt (cash) (\$m)				-15.5
Implied Valuation				89.0
Per Share				0.38
				0.50
Target PE Multiple				
EPS (c)				3.2
PE Target (x)				12.0
Per Share				0.38
Discounted Cash Flow				
Cool of a soll of	14.5%	WACC		14.5%
Cost of equity Cost of debt	6.0%	TGR		

Source: Company reports and Canaccord Genuity



# **Appendix: Important Disclosures**

#### Analyst Certification

Each authoring analyst of Canaccord Genuity (Australia) Limited whose name appears on the front page of this research hereby certifies that (i) the recommendations and opinions expressed in this research accurately reflect the authoring analyst's personal, independent and objective views about any and all of the designated investments or relevant issuers discussed herein that are within such authoring analyst's coverage universe and (ii) no part of the authoring analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by the authoring analyst in the research. Analysts employed outside the US are not registered as research analysts with FINRA. These analysts may not be associated persons of Canaccord Genuity Inc. and therefore may not be subject to the NASD Rule 2711 and NYSE Rule 472 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

#### Site Visit Disclaimer\*\*

A site visit has been conducted.

#### Analyst (Long Position) Disclaimer\*\*

The primary analyst and associate analyst have a long position in the shares or derivatives, or has any other financial interest in AVA Risk Group, the value of which increases as the value of the underlying equity increases.

#### **General Disclosures**

"Canaccord Genuity" is the business name used by certain wholly owned subsidiaries of Canaccord Genuity Group Inc., including Canaccord Genuity Inc., Canaccord Genuity Limited, Canaccord Genuity Corp., and its affiliated companies that are 80%-owned by Canaccord Genuity Group Inc. - Canaccord Genuity Financial Limited and Canaccord Genuity (Australia) Limited.

The authoring analysts who are responsible for the preparation of this research are employed by Canaccord Genuity (Australia) Limited ABN 19 075 071 466 holder of AFS Licence No 234666 which is regulated by the Australian Securities and Investment Commission (ASIC).

The authoring analysts who are responsible for the preparation of this research have received (or will receive) compensation based upon (among other factors) the Corporate Finance/Investment Banking revenues and general profits of Canaccord Genuity. However, such authoring analysts have not received, and will not receive, compensation that is directly based upon or linked to one or more specific Corporate Finance/Investment Banking activities, or to recommendations contained in the research.

Canaccord Genuity (Australia) Limited and its affiliated companies may have a Corporate Finance/ Investment Banking or other relationship with the issuer that is the subject of this research and may trade in any of the designated investments mentioned herein either for their own account or the accounts of their customers, in good faith or in the normal course of market making. Accordingly, Canaccord Genuity (Australia) Limited or their affiliated companies, principals or employees (other than the authoring analyst(s) who prepared this research) may at any time have a long or short position in any such designated investments, related designated investments or in options, futures or other derivative instruments based thereon.

Some regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of research. This research has been prepared in accordance with Canaccord Genuity (Australia) Limited's policy on managing conflicts of interest, and information barriers or firewalls have been used where appropriate. Canaccord Genuity (Australia) Limited's policy is available upon request. The information contained in this research has been compiled by Canaccord Genuity (Australia) Limited from sources believed to be reliable, but (with the exception of the information about Canaccord Genuity) no representation or warranty, express or implied, is made by Canaccord Genuity (Australia) Limited, its affiliated companies or any other person as to its fairness, accuracy, completeness or correctness. Canaccord Genuity has not independently verified the facts, assumptions, and estimates contained herein. All estimates, opinions and other information contained in this research constitute Canaccord Genuity (Australia) Limited's judgment as of the date of this research, are subject to change without notice and are provided in good faith but without legal responsibility or liability.

Canaccord Genuity's salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients and our proprietary trading desk that reflect opinions that are contrary to the opinions expressed in this research. Canaccord Genuity's affiliates, principal trading desk, and investing businesses may make investment decisions that are inconsistent with the recommendations or views expressed in this research.

This research is provided for information purposes only and does not constitute an offer or solicitation to buy or sell any designated investments discussed herein in any jurisdiction where such offer or solicitation would be prohibited. As a result, the designated investments discussed in this research may not be eligible for sale in some jurisdictions. This research is not, and under no circumstances should be construed as, a solicitation to act as a securities broker or dealer in any jurisdiction by any person or company that is not legally permitted to carry on the business of a securities broker or dealer in that jurisdiction. This material is prepared for general circulation to clients and does not have regard to the investment objectives, financial situation or particular needs of any particular person. Investors should obtain advice based on their own individual circumstances before making an investment decision. To the fullest extent permitted by law, none of Canaccord Genuity (Australia) Limited, its affiliated companies or any other person accepts any liability whatsoever for any direct or consequential loss arising from or relating to any use of the information contained in this research.

#### For Australian Residents

This research is distributed in Australia by Canaccord Genuity (Australia) Limited ABN 19 075 071 466 holder of AFS Licence No 234666. To the extent that this research contains any advice, this is limited to general advice only. Recipients should take into account their own personal circumstances before making an investment decision. Clients wishing to effect any transactions should do so through a qualified representative of Canaccord Genuity (Australia) Limited or its Wealth Management affiliated company, Canaccord Genuity Financial Limited ABN 69 008 896 311 holder of AFS Licence No 239052.

#### For Canadian Residents

This research has been approved by Canaccord Genuity Corp., which accepts sole responsibility for this research and its dissemination in Canada. Canaccord Genuity Corp. is registered and regulated by the Investment Industry Regulatory Organization of Canada (IIROC) and is a Member of the Canadian Investor Protection Fund. Canadian clients wishing to effect transactions in any designated investment discussed should do so through a qualified salesperson of Canaccord Genuity Corp. in their particular province or territory.

#### For United Kingdom and European Residents This research is distributed in the United Kingdom and elsewhere Europe, as third party research by Canaccord Genuity Limited, which is authorized and regulated by the Financial Conduct Authority. This research is for distribution only to persons who are Eligible Counterparties or Professional Clients only and is exempt from the general restrictions in section 21 of the Financial Services and Markets Act 2000 on the communication of invitations or inducements to engage in investment activity on the grounds that it is being distributed in the United Kingdom only to persons of a kind described in Article 19(5) (Investment Professionals) and 49(2) (High Net Worth companies, unincorporated associations etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended). It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons. This material is not for distribution in the United Kingdom or elsewhere in Europe to retail clients, as defined under the rules of the Financial Conduct Authority.

#### For United States Residents

These materials are not for distribution in the United States or to US Persons," as defined under Rule 902 promulgated under the United States Securities Act of 1933, as amended. Nothwithstanding the foregoing, these materials may be distributed by Canaccord Genuity (Australia) Limited in the United States to "major US institutional investors," as defined under Rule 15a-6 promulgated under the US Securities Exchange Act of 1934, as amended, and as interpreted by the staff of the US Securities and Exchange Commission ("SEC").

#### For Hong Kong Residents

This research is distributed in Hong Kong by Canaccord Genuity (Hong Kong) Limited which is licensed by the Securities and Futures Commission. This research is only intended for persons who fall within the definition of professional investor as defined in the Securities and Futures Ordinance. It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons. Recipients of this report can contact Canaccord Genuity (Hong Kong) Limited. (Contact Tel: +852 3919 2561) in respect of any matters arising from, or in connection with, this research.

Additional information is available on request.

Copyright © Canaccord Genuity Corp. 2020. – Member IIROC/Canadian Investor Protection Fund Copyright © Canaccord Genuity Limited 2020. – Member LSE, authorized and regulated by the Financial Conduct Authority.

Copyright © Canaccord Genuity Inc. 2020 -Member FINRA/ SIPC.

Copyright © Canaccord Genuity (Australia) Limited 2020. – Participant of ASX Group and Chi-x Australia. Authorized and regulated by ASIC. Copyright © Canaccord Genuity Financial Limited 2020.

All rights reserved. All material presented in this document, unless specifically indicated otherwise, is under copyright to Canaccord Genuity Corp., Canaccord Genuity Limited, Canaccord Genuity Inc or Canaccord Genuity Group Inc. None of the material, nor its content, nor any copy of it, may be altered in any way, or transmitted to or distributed to any other party, without the prior express written permission of the entities listed above.

#### Sydney

Level 62, MLC Centre, 19 Martin Place, Sydney NSW, 2000, Australia Ph: +61 2 9263 2700

#### Melbourne

Level 15, 333 Collins Street, Melbourne, VIC, 3000, Australia Ph: +61 3 8688 9100

#### Perth

Level 23, Exchange Tower, 2 The Esplanade, Perth, WA, 6000 Ph: +61 8 9263 1111

